NDC-11 (Package) | NDC-9 (Product) (Ascending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00085-4348-01 | 00085-4348 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Oct. 18, 2020 | In Use | ||
00085-4349-01 | 00085-4349 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Oct. 18, 2020 | In Use | ||
00085-4350-01 | 00085-4350 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00085-4351-01 | 00085-4351 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00085-4352-01 | 00085-4352 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00088-1111-14 | 00088-1111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Sept. 19, 1996 | March 31, 2015 | No Longer Used |
00088-1202-05 | 00088-1202 | Dolasetron mesylate | Anzemet | 50.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | June 30, 2017 | No Longer Used |
00088-1202-43 | 00088-1202 | Dolasetron mesylate | Anzemet | 50.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | Aug. 31, 2011 | No Longer Used |
00088-1203-05 | 00088-1203 | Dolasetron mesylate | Anzemet | 100.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | June 30, 2017 | No Longer Used |
00088-1203-29 | 00088-1203 | Dolasetron mesylate | Anzemet | 100.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | March 31, 2006 | No Longer Used |
00088-1203-43 | 00088-1203 | Dolasetron mesylate | Anzemet | 100.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | Oct. 31, 2012 | No Longer Used |
00088-1206-32 | 00088-1206 | Dolasetron mesylate | Anzemet | 100.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 11, 1997 | Sept. 30, 2017 | No Longer Used |
00088-1208-06 | 00088-1208 | Dolasetron mesylate | Anzemet | 12.5 mg/.625mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 11, 1997 | Aug. 31, 2016 | No Longer Used |
00088-1208-76 | 00088-1208 | Dolasetron mesylate | Anzemet | 12.5 mg/.625mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 11, 1997 | Nov. 9, 2012 | No Longer Used |
00088-1209-26 | 00088-1209 | Dolasetron mesylate | Anzemet | 500.0 mg/25mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 11, 1997 | June 30, 2016 | No Longer Used |
00089-0610-12 | 00089-0610 | Imiquimod | Aldara | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | June 24, 2011 | Jan. 31, 2015 | No Longer Used | |
00093-0220-01 | 00093-0220 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Oct. 31, 2019 | No Longer Used |
00093-0220-56 | 00093-0220 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Oct. 31, 2019 | No Longer Used |
00093-0233-19 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 16, 2009 | Oct. 31, 2015 | No Longer Used | |
00093-0233-33 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Jan. 31, 2015 | No Longer Used | |
00093-0233-56 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Oct. 31, 2015 | No Longer Used | |
00093-0233-93 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 21, 2010 | Aug. 31, 2013 | No Longer Used | |
00093-0782-01 | 00093-0782 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Feb. 21, 2003 | Feb. 28, 2019 | No Longer Used | |
00093-0782-05 | 00093-0782 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 9, 2008 | May 31, 2018 | No Longer Used | |
00093-0782-10 | 00093-0782 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 9, 2008 | May 31, 2018 | No Longer Used |
Found 10,000 results in 4 milliseconds — Export these results